LY294002 is a potent, reversible, ATP-competitive PI3K inhibitor. It affects PI3K/Akt/mTOR and NF-κB signaling by binding to the PI3K ATP-binding site and blocking Akt phosphorylation, effectively inhibiting cell proliferation, EMT, and angiogenesis while promoting apoptosis.
LY294002 Mechanism of Action: PI3K Inhibition in Tumor Cell Research
LY294002 MOA：Targeting PI3K/AKT Signaling Pathway for Oncology Research